Gun companies made more than $1 billion from assault weapon sales over a decade, House panel says

Gun companies made more than  billion from assault weapon sales over a decade, House panel says


Fire arms are seen at the Bobâs Little Sport Gun Shop in the town of Glassboro, New Jersey, United States on May 26, 2022. 

Tayfun Coskun | Anadolu Agency | Getty Images

Major gun manufacturers have made over $1 billion in the last decade selling military-style assault weapons, according to an investigation by the House Committee on Oversight and Reform.

A memo from the panel outlines manufacturers’ revenue and marketing strategies for assault-style weapons, focusing on the the gun brands used in recent mass shootings. The release came ahead of a Wednesday hearing on the role of the firearms industry in pervasive gun violence in the United States.

Earnings from assault weapons more than doubled for brands like Smith & Wesson, Sturm Ruger and Daniel Defense between 2019 and 2021, according to House findings. Sturm Ruger CEO Christopher Killoy, and Daniel Defense CEO Marty Daniel are set to testify at Wednesday’s hearing. Smith & Wesson CEO Mark Smith was invited but won’t attend.

At the hearing, Chairwoman Rep. Carolyn B. Maloney, D-N.Y., announced that the committee will issue subpoenas to Smith & Wesson and other manufacturers.

The committee also provided estimated assault weapon revenues for these companies since 2012, the year a gunman killed 20 children and six adults at Sandy Hook Elementary School in Connecticut:

  • Smith & Wesson: $695 million
  • Sturm Ruger: $514 million
  • Daniel Defense: $528 million
  • SIG Sauer: Refused to report
  • Bushmaster: $2.9 million (2021 only)

The number of recent mass shooting deaths was also listed for each company, with assault weapons from all five brands used in at least two recent massacres. The gunman who killed 19 children and two teachers in May at Robb Elementary School in Uvalde, Texas, used a weapon made by Daniel Defense.

The brands themselves do not track deaths, injuries or crimes that involve their weapons. Sig Sauer told the committee that it does “not have the means” to track deaths. Sturm Ruger said it learns of incidents through its “customer service department,” the media or from occasional lawsuits.

The hearing comes just after California Gov. Gavin Newsom recently signed a law allowing citizens affected by gun violence to sue manufacturers.

The committee also focused on marketing tactics, including Smith & Wesson advertisements that mimic first-person shooter video games and a Sig Sauer weapon sold as an “apex predator.”

House Democrats are pushing to vote on an assault weapons ban later this week. If passed, the bill is unlikely to make it through the Senate.

Smith & Wesson, Sig Sauer and Sturm Ruger did not immediately respond to a request for comment.



Source

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to  billion
Health

OpenEvidence, the ‘ChatGPT for doctors,’ doubles valuation to $12 billion

A startup widely known as “ChatGPT for doctors” raised a new funding round that values the company at $12 billion. OpenEvidence, based in Miami, Florida, closed a $250 million financing, led by Thrive Capital and DST, the company told CNBC. The startup first raised outside capital in February, when it reeled in $75 million from […]

Read More
Another alliance of health care and AI signals why pharma stocks should be back in favor
Health

Another alliance of health care and AI signals why pharma stocks should be back in favor

Bristol Myers Squibb and Microsoft ‘s new partnership aimed at accelerating early detection of lung cancer marks the latest way health care and artificial intelligence are rapidly intersecting. Bristol Myers said on Tuesday it will work with Microsoft’s AI-powered radiology platform to develop and launch imaging algorithms. These new tools, which can be used to […]

Read More
Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
Health

Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry

US President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025. Will Oliver | Bloomberg | Getty Images Drug pricing. Looming patent cliffs. Dealmaking. The first year of Trump 2.0. Those are among the themes that dominated conversations last week as drugmakers […]

Read More